Head to head
Akso Health vs McKesson
Side-by-side on the measures that matter, with a plain-English read. Full detail: AHG · MCK
AHG
Akso Health
1.21+3.42%
1-year price shape — -26% over the period
Quant Rating F · 36/100
vs
MCK
McKesson
910.33-1.23%
1-year price shape — +22% over the period
Quant Rating C · 65/100
1-year performance, rebased to 100
McKesson edges it on the scoreable measures. McKesson has the highest Quant Rating (65); McKesson has done best over the past year (+22%); McKesson pays the highest dividend yield.
| AHG | MCK | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Distribution |
| Last price | 1.21 | 910.33 |
| Change today | +3.42% | -1.23% |
| 1-year return | -25.8% | +21.8% |
| Market cap | $1.04B | $106.14B |
| 52-week range | 0.68 – 2.50 | 722.11 – 996.84 |
| Valuation | ||
| P/E (TTM) | -40.33 | 24.31 |
| P/E percentile, own 5-yr range | 1st | 45th |
| P/B | 5.73 | -25.03 |
| Dividend yield | 0.00% | 0.36% |
| Profitability & growth | ||
| EPS (TTM) | -0.03 | 38.55 |
| Net profit (TTM) | $-25.70M | $4.49B |
| Revenue (TTM) | $-42.12M | $410.98B |
| Revenue growth (YoY) | +25.5% | +7.7% |
| Gross margin | -0.1% | 3.6% |
| Operating margin | -28.9% | 1.7% |
| Net margin | -135.0% | 1.1% |
| Free cash flow (TTM) | -- | $6.15B |
| Ownership & sentiment | ||
| Institutional ownership | 0.3% | 92.0% |
| Insider activity (12mo) | 0 buy / 0 sell | 23 buy / 25 sell |
| Short interest (% of float) | 0.0% | 2.5% |
| Analyst consensus | -- | 83% buy / 17% hold (12) |
| Analyst price target | -- | $1,001 (+10%) |
| StockVane view | ||
| StockVane Quant Rating | F (36) | C (65) |
| Company | ||
| Employees | 12 | 43,000 |
| Founded | 2014 | 1833 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.